Alliance for Multispecialty Research Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Alliance for Multispecialty Research's estimated annual revenue is currently $59.5M per year.(i)
  • Alliance for Multispecialty Research's estimated revenue per employee is $201,000

Employee Data

  • Alliance for Multispecialty Research has 296 Employees.(i)
  • Alliance for Multispecialty Research grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$145.5M5170%$28.5MN/A
#2
$102.7M5117%N/AN/A
#3
$58.7M2921%N/AN/A
#4
$8.2M41-2%N/AN/A
#5
$22.5M11212%$23.6MN/A
#6
$5.6M284%N/AN/A
#7
$11.3M568%N/AN/A
#8
$13.1M657%N/AN/A
#9
$7.6M3815%N/AN/A
#10
$7.2M363%N/AN/A
Add Company

The Art of Clinical Research Perfected! The Alliance for Multispecialty Research (AMR) is a clinical research company of 17 of the most highly experienced clinical research centers in the U.S. Over the past 23 years, AMR centers have enrolled over 145,000 subjects and completed more than 9,500 Phase I-IV clinical trials across a broad range of therapeutic areas, including studies evaluating pharmacokinetics, pharmacodynamics, and bioequivalent/bioavailability. AMR's combined internal database of over 225,000 potential study volunteers, along with our physician databases of more than 1.3 million patients, allow us to perform detailed searches to promptly identify prospective subjects. Our proven experience, streamlined processes, and vast resources empower us to consistently meet or exceed study enrollment targets. We employ intentional strategies designed to optimize enrollment and retention, resulting in an average enrollment rate of more than 110%, and an average retention rate of more than 92% for general out-patient studies and more than 96% for vaccine-specific trials. AMR offers flexible solutions tailored to each protocol's unique requirements. We can coordinate multi-center studies through centralized processes, maximizing economies of scale and minimizing timeframes to best serve our clients by using single-point-of-contact communication and standardization of study budgets, contracts, payments, and source documents. Centralization results not only in shortened timelines and increased savings to our clients, but also enables sponsors and CROs to engage multiple centers simultaneously instead of dealing with each center on an individual basis. However, AMR also offers sponsors and CRO's a direct-to-site options, allowing companies to contract directly with individual locations.

keywords:N/A

N/A

Total Funding

296

Number of Employees

$59.5M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alliance for Multispecialty Research's People

NameTitleEmail/Phone
1
Clinical Research CoordinatorReveal Email/Phone
2
VP OperationsReveal Email/Phone
3
Senior Clinical Research CoordinatorReveal Email/Phone
4
SVP OperationsReveal Email/Phone
5
Chief Financial and Administrative Officer, SVPReveal Email/Phone
6
Clinical Research AssistantReveal Email/Phone
7
General ManagerReveal Email/Phone
8
Regulatory Specialist and LPNReveal Email/Phone
9
General ManagerReveal Email/Phone
10
Site AdministratorReveal Email/Phone

Alliance for Multispecialty Research News

2022-04-17 - Ballad Health, East Tennessee State University Research ...

The new Appalachian Highlands Rural Innovation and Entrepreneurship Alliance will coordinate multiple local and national areas of research...

2022-03-22 - Curewell Capital acquires the Alliance for Multispecialty ...

KNOXVILLE, Tenn., March 21, 2022 /PRNewswire/ -- The Alliance for Multispecialty Research ("AMR"), one of the largest independent commercial...

2022-03-22 - Curewell debut buy of AMR

... a majority stake in the Alliance for Multispecialty Research (AMR), ... Zoom in: Curewell is partnering with the clinical research site...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$72.1M298-7%N/A
#2
$59.2M299N/AN/A
#3
$118.6M3116%N/A
#4
$119.6M330N/AN/A
#5
$59.7M3364%$35.9M